Press release, 1 December 2022
Combat Medical is pleased to announce the results of the HIVEC I phase 3 randomised controlled trial, published in European Urology Oncology on 23 November 2022.
As with this year’s HIVEC II publication, this short-term regimen shows equivalence to the use of cold chemotherapy. However, in combination with the findings from our other study in Spain, HIVEC E, it demonstrates that longer-term therapy leads to a further 20% improvement in results.
Combat Medical CEO Edward Bruce-White said: “We are delighted to publish our HIVEC I results, having worked with 13 centres across Spain between 2014 and 2020. The finalisation of our oldest clinical trial allows us to continue to build on our knowledge of HIVEC’s place in the treatment of bladder cancer and we are confident our therapy has a significant role to play in the treatment of this under-investigated disease.
“We are also pleased to see the treatment is so well tolerated, with many other alternative therapies leading to unacceptable side effects adding to the suffering of this large patient population. We would like to thank Dr Angulo, Professor Palou and all of the contributors for their hard work.”
Combat Medical is currently awaiting publication of several other studies, and its largest study to date starts in the UK early next year.
Edward Bruce-White added: “We have performed over 75,000 treatments in 41 countries and are looking forward to a brighter future for our patients.”
For further information, contact:
Guy Cooper, Sales and Marketing Director, Combat Medical
Email: grc@combat-medical.com
About Combat Medical
Combat Medical Ltd is a UK-based medical device company with a platform technology for heating and circulating chemotherapy for bladder cancer and cancers of the abdomen and peritoneum. With over 75,000 treatments completed in more than 41 countries, Combat leads the global development and clinical use of device-assisted therapies to treat many common cancers, including bladder cancer, colorectal cancer, ovarian cancer and pancreatic cancer. With 20+ clinical trials already published and many more underway, Combat continues to drive and support the research in this area.
